GlassScriptPhysician profile
Stephen Lacaze
NPI 1023596053
$2,306.46
in general payments reported to CMS, 2019-2025
22 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $30.03 · 2024: $425 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.55 | 2021-2025 | |
| Axsome Therapeutics, INC. | $340.79 | 2024-2025 | Auvelity |
| Ardelyx, INC. | $318.28 | 2025 | Ibsrela |
| Vanda Pharmaceuticals INC. | $198.74 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.25 | 2025 | Caplyta |
| Lilly USA, LLC | $112.03 | 2024-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $107.43 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $86.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.52 | 2024-2025 | Relistor, Trulance, Xifaxan |
| Novo Nordisk INC | $76.90 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $74.84 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $72.72 | 2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $55.84 | 2024-2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $38.64 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $32.43 | 2024-2025 | Airsupra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.71 | 2025 | Trintellix |
| Sk Life Science, INC. | $30.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.34 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $21.79 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $17.56 | 2025 | |
| Amarin Pharma, INC. | $16.08 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lacaze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.